Download PDF
Osteologie 2018; 27(04): 194-199
DOI: 10.1055/s-0038-1676922
Seltene Knochenerkrankungen – Rare bone diseases
Georg Thieme Verlag KG Stuttgart · New York

Pathophysiologie und Therapie der Osteogenesis imperfecta

Pathophysiology and treatment in Osteogenesis imperfecta
O. Semler
1   Klinik für Kinder- und Jugendmedizin, Uniklinik Köln
,
M. Rehberg
1   Klinik für Kinder- und Jugendmedizin, Uniklinik Köln
,
H. Hoyer-Kuhn
1   Klinik für Kinder- und Jugendmedizin, Uniklinik Köln
› Author Affiliations
Further Information

Publication History

eingereicht: 02 August 2018

angenommen: 19 September 2018

Publication Date:
18 December 2018 (online)

    Permissions and Reprints

Zusammenfassung

Die Osteogenesis imperfecta (OI) ist die häufigste angeborene Skeletterkrankung im Kindes- und Jugendalter. Sie beruht in den meisten Fällen auf Mutationen, die die Kollagensynthese beeinträchtigen. Bei sehr unterschiedlichen Verlaufsformen besteht keine klare Genotyp-Phänotyp-Korrelation. Führendes Symptom sind rezidivierende Frakturen bei inadäquaten Traumata, aber auch extra-skelettale Symptome wie eine Muskelhypotonie oder Schwerhörigkeit gehören dazu. Die Therapie beinhaltet orthopädisch/chirurgische Maßnahmen zur Frakturversorgung und Korrektur von Deformierungen. Die medikamentöse Behandlung beschränkt sich im Kindesalter auf antiresorptive Medikamente wie Bisphosphonate oder das in Erprobung befindliche Denosumab. Nach Ende des Wachstums werden auch osteoanabole Medikamente eingesetzt. Wichtigste Maßnahme zur Anregung des Knochenaufbaus ist die Kräftigung der Muskulatur durch Physiotherapie und Rehabilitation. Um diese Maßnahmen auf einander abzustimmen und Erfahrungen für weitere Therapieverbesserungen zu sammeln, sollte die Behandlung dieser Patienten in spezialisierten Zentren erfolgen.

Summary

Osteogenesis imperfecta (OI) is the most frequent hereditary bone disease during childhood. In most cases OI is caused by mutations affecting collagen production. Phenotypes of patients differ substantially and there is no clear genotype-phenotype correlation. Main symptom is an increased fracture rate due to inadequate traumata. Additionally, extra-skelettale signs like muscle hypotonia and hearing impairments are frequently reported. The multimodular therapy includes surgical procedures to treat fractures and to correct deformities. During childhood drug therapy is limited to the use of bisphosphonates. Other antiresorptive drugs like Denosumab are currently under investigation. After end of growth osteoanabolic agents like Teriparatide or Antisclerostin can be used. Most important is a regular training including physiotherapy and rehabilitation. To coordinate these therapies the care of the patients need to be centralized. Such a treatment in specialized centers will allow to learn more about natural history of the disease and to improve the care.

Schlüsselwörter

Osteogenesis imperfecta - Therapie - Pathophysiologie - Bisphosphonate

Keywords

Osteogenesis imperfecta - therapy - pathophysiology - bisphosphonates
 

  • Literatur

  • 1 Hoyer-Kuhn H, Bartz-Seel J, Blickheuser R. et al. Diagnostik und Therapie der Osteogenesis imperfecta. Monatsschrift Kinderheilkunde 2016; 165: 333-346.
    Google Scholar
  • 2 Marini JC, Forlino A, Bachinger HP. et al. Osteogenesis imperfecta. Nat Rev Dis Primers 2017; 03: 17052.
    CrossrefPubMedGoogle Scholar
  • 3 Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization density of iliac crest bone from children with osteogenesis imperfecta. Calcif Tissue Int 1999; 64: 185-190.
    CrossrefPubMedGoogle Scholar
  • 4 Schramm T, Gloning KP, Minderer S. et al. Prenatal sonographic diagnosis of skeletal dysplasias. Ultrasound Obstet Gynecol 2009; 34: 160-170.
    PubMedGoogle Scholar
  • 5 Kidszun A, Linebarger J, Walter JK. et al. What If the prenatal diagnosis of a lethal anomaly turns out to be wrong?. Pediatrics 2016; 137.
    Google Scholar
  • 6 Pontz BF, Stoss H, Spranger J. Heterogeneity in osteogenesis imperfecta: clinical and morphological findings. Ann N Y Acad Sci 1988; 543: 30-39.
    CrossrefPubMedGoogle Scholar
  • 7 Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-1385.
    CrossrefPubMedGoogle Scholar
  • 8 Andersson K, Dahllof G, Lindahl K. et al. Mutations in COL1A1 and COL1A2 and dental aberrations in children and adolescents with osteogenesis imperfecta – A retrospective cohort study. PLoS One 2017; 12: e0176466.
    CrossrefPubMedGoogle Scholar
  • 9 Kuurila K, Grenman R, Johansson R, Kaitila I. Hearing loss in children with osteogenesis imperfecta. Eur J Pediatr 2000; 159: 515-519.
    CrossrefPubMedGoogle Scholar
  • 10 Kuurila K, Kaitila I, Johansson R, Grenman R. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. Ann Otol Rhinol Laryngol 2002; 111: 939-946.
    CrossrefPubMedGoogle Scholar
  • 11 Al-Senaidi KS, Ullah I, Javad H, Al-Khabori M, Al-Yaarubi S. Echocardiographic Evidence of Early Diastolic Dysfunction in Asymptomatic Children with Osteogenesis Imperfecta. Sultan Qaboos Univ Med J 2015; 15: e456-e462.
    CrossrefPubMedGoogle Scholar
  • 12 Folkestad L, Hald JD, Gram J. et al. Cardiovascular disease in patients with osteogenesis imperfecta – a nationwide, register-based cohort study. Int J Cardiol 2016; 225: 250-257.
    CrossrefPubMedGoogle Scholar
  • 13 Forlino A, Marini JC. Osteogenesis imperfecta. Lancet 2016; 387: 1657-1671.
    CrossrefPubMedGoogle Scholar
  • 14 Rauch F, Husseini A, Roughley P, Glorieux FH, Moffatt P. Lack of circulating pigment epitheliumderived factor is a marker of osteogenesis imperfecta type VI. J Clin Endocrinol Metab 2012; 97: E1550-E1556.
    CrossrefPubMedGoogle Scholar
  • 15 Becker J, Semler O, Gilissen C. et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet 2011; 88: 362-371.
    CrossrefPubMedGoogle Scholar
  • 16 Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006; 148: 456-460.
    CrossrefPubMedGoogle Scholar
  • 17 Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-68.
    CrossrefPubMedGoogle Scholar
  • 18 Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
    CrossrefPubMedGoogle Scholar
  • 19 Gatti D, Antoniazzi F, Prizzi R. et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-763.
    PubMedGoogle Scholar
  • 20 Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2012; 25: 485-491.
    PubMedGoogle Scholar
  • 21 Bishop N, Adami S, Ahmed SF. et al. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 2013; 382: 1424-1432.
    CrossrefPubMedGoogle Scholar
  • 22 Sarraf KM. Images in clinical medicine. Radiographic zebra lines from cyclical pamidronate therapy. N Engl J Med 2011; 365: e5.
    CrossrefPubMedGoogle Scholar
  • 23 Hoyer-Kuhn H, Franklin J, Allo G. et al. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. J Musculoskelet Neuronal Interact 2016; 16: 24-32.
    PubMedGoogle Scholar
  • 24 Simm PJ, Biggin A, Zacharin MR. et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 2018; 54: 223-233.
    CrossrefPubMedGoogle Scholar
  • 25 Smith-Bindman R, Steiger P, Cummings SR, Genant HK. The index of radiographic area (IRA): a new approach to estimating the severity of vertebral deformity. Bone Miner 1991; 15: 137-149.
    CrossrefPubMedGoogle Scholar
  • 26 Sumnik Z, Land C, Rieger-Wettengl G, Korber F, Stabrey A, Schoenau E. Effect of pamidronate treatment on vertebral deformity in children with primary osteoporosis. A pilot study using radiographic morphometry. Horm Res 2004; 61: 137-142.
    CrossrefPubMedGoogle Scholar
  • 27 Koerber F, Schulze UUphoff, Koerber S, Schonau E, Maintz D, Semler O. Introduction of a new standardized assessment score of spine morphology in osteogenesis imperfecta. Rofo 2012; 184: 719-725.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Orwoll ES, Shapiro J, Veith S. et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest 2014; 124: 491-498.
    CrossrefPubMedGoogle Scholar
  • 29 Gatti D, Rossini M, Viapiana O. et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int 2013; 93: 448-452.
    CrossrefPubMedGoogle Scholar
  • 30 Glorieux FH, Devogelaer JP, Durigova M. et al. BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial. J Bone Miner Res 2017; 32: 1496-1504.
    CrossrefPubMedGoogle Scholar
  • 31 Chan JK, Gotherstrom C. Prenatal transplantation of mesenchymal stem cells to treat osteogenesis imperfecta. Front Pharmacol 2014; 05: 223.
    Google Scholar
  • 32 Hoyer-Kuhn H, Semler O, Stark C, Struebing N, Goebel O, Schoenau E. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact 2014; 14: 445-453.
    PubMedGoogle Scholar
  • 33 Mueller B, Engelbert R, Baratta-Ziska F. et al. Consensus statement on physical rehabilitation in children and adolescents with osteogenesis imperfecta. Orphanet Journal of Rare Diseases 2018; 13: 158.
    CrossrefPubMedGoogle Scholar
  • 34 Wirth T. [Osteogenesis imperfecta]. Orthopade 2012; 41: 773-782 quiz 83-84..
    CrossrefPubMedGoogle Scholar
  • 35 Ruck J, Dahan-Oliel N, Montpetit K, Rauch F, Fassier F. Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year. J Child Orthop 2011; 05: 217-224.
    CrossrefPubMedGoogle Scholar
  • 36 Ramaswamy R, Kosashvili Y, Cameron H. Bilateral total hip replacement in osteogenesis imperfecta with hyperplastic callus. J Bone Joint Surg Br 2009; 91: 812-814.
    CrossrefPubMedGoogle Scholar